Details for Patent: 9,119,859

Which drugs does patent 9,119,859 protect, and when does it expire?

Patent 9,119,859 protects XTORO and is included in one NDA.

This patent has twenty-two patent family members in sixteen countries.

Summary for Patent: 9,119,859

Title:	Methods for treating otic infections
Abstract:	The present invention relates to methods for treating an ophthalmic, otic, or nasal infection comprising treating the infected tissue with a composition comprising finafloxacin or a finafloxacin derivative. The present invention also relates to antimicrobial compositions comprising finafloxacin or a finafloxacin derivative. The compositions are suitable for the treatment of ophthalmic, otic, or nasal infections.
Inventor(s):	David W. Stroman, Masood A. Chowhan, Kenneth C. Appell
Assignee:	Curofin Pharma GmbH
Application Number:	US13/967,897
Patent Claim Types: see list of patent claims	Use; Composition;

United States Patent 9,119,859 Landscape: Scope, Claim Boundaries, and How Finafloxacin Otic Method-of-Use Claims Affect Generic and License Strategy

Executive summary: U.S. Patent 9,119,859 claims a narrow, method-of-use treatment of acute otitis externa (AOE) or acute otitis media (AOM) specifically when tympanostomy tubes are in place, using a topical otic composition containing finafloxacin instilled in the external ear canal. The dependent claims add hard formulation bounds: 0.3 to 0.4 w/v% finafloxacin, pH 5.0 to 6.0, optional magnesium chloride (0.3 to 1.0 w/v%), and an anti-inflammatory agent limited to dexamethasone at 0.01 to 1.0 wt.%. The most practical “design around” levers are removing the tympanostomy-tube condition from the claim pathway, shifting outside the specified finafloxacin/pH/magnesium windows, or changing the anti-inflammatory agent away from dexamethasone.

---

What is U.S. Patent 9,119,859 scope for finafloxacin topical treatment with tympanostomy tubes?

Short answer: The patent is directed to instilling finafloxacin topical otic compositions for acute otitis externa or acute otitis media in a subject with tympanostomy tubes, delivered into the external ear canal.

Claim architecture and claim “must-haves”

The six claims you provided follow a typical method-of-treatment cascade:

• Claim 1 (independent):
  Method for treating AOE or AOM with tympanostomy tubes, by instilling a topical otic composition comprising finafloxacin into the external ear canal.

• Claim 2 (concentration + pH):
  Adds specific finafloxacin concentration (0.3 to 0.4 w/v%) and composition pH (5.0 to 6.0).

• Claim 3 (salt excipient bound):
  Adds magnesium chloride (0.3 to 1.0 w/v%).

• Claim 4 (anti-inflammatory agent):
  Adds that the otic composition further includes an anti-inflammatory agent.

• Claim 5 (agent identity):
  Limits the anti-inflammatory agent to dexamethasone.

• Claim 6 (steroid level bound):
  Binds dexamethasone concentration to 0.01 to 1.0 wt.%.

Practical scope boundary: “method” vs “composition”

Even if the composition is described in terms of ingredients, the claims are drafted as a method. That changes infringement dynamics:

• Proof of infringement typically requires evidence that a clinician or patient performs the method steps: treating the indicated condition with tubes and instilling the composition into the external ear canal.
• A generic “composition-only” sale can still create exposure depending on labeling, instructions, and induced infringement theories, but the independent claim text points directly to administration.

Medical-configuration gating: tympanostomy tubes

Claim 1 is conditioned on “a subject” who has tympanostomy tubes. This is a strong gating element:

• Products still containing finafloxacin could avoid claim 1 if the commercial product is positioned and used exclusively in patients without tubes (not a guarantee, but it shifts risk).
• Clinical trial design, indications, and label language become central to enforceability.

---

Which elements of claim 1 create the strongest infringement risk for generic finafloxacin otic products?

Short answer: The highest-risk elements are: (1) topical instillation into the external ear canal, (2) use for AOE or AOM, and (3) the presence of tympanostomy tubes.

Element-by-element analysis of claim 1

1. “Acute otitis externa or acute otitis media”
   This ties to disease states. A product with a label limited to another diagnosis (eg, chronic suppurative otitis media) would reduce alignment with the claimed “treating” step, though off-label use can still carry risk.

2. “with tympanostomy tubes”
   This is the differentiator vs many otic antimicrobial claims that do not specify tube status. It limits the class of “subjects” performing/receiving the treatment.

3. “topical otic composition comprising finafloxacin”
   “Comprising” leaves room for additional excipients without avoiding claim coverage, unless avoidance is achieved via other limitations in dependent claims.

4. “instilling … into the external ear canal”
   This favors otic delivery formulations intended for ear canal instillation. It makes non-otic delivery or different anatomical placement a potential design-around.

Claim 1 likely reads on “finafloxacin otic drops/solution”

Without seeing the specification and definitions, the plain meaning suggests typical otic drops/suspensions. Any device that results in instillation into the external ear canal risks capture.

---

How do claims 2 and 3 narrow infringement with finafloxacin concentration, pH, and magnesium chloride?

Short answer: Claims 2 and 3 are formulation-range locks. Staying outside those windows is the primary technical design-around for the dependent claims, though claim 1 can still be asserted if a product remains a finafloxacin otic instilled for the claimed tube-related indications.

Claim 2: finafloxacin 0.3 to 0.4 w/v% and pH 5.0 to 6.0

• Finafloxacin concentration: 0.3–0.4 w/v%
• pH: 5.0–6.0

Design-around levers:

• Move finafloxacin concentration below 0.3 w/v% or above 0.4 w/v%.
• Move pH outside 5.0–6.0.

Claim 3: magnesium chloride 0.3 to 1.0 w/v%

Claim 3 adds an excipient concentration window, but only if the composition includes magnesium chloride at that range.

Design-around levers:

• Omit magnesium chloride entirely.
• Keep magnesium chloride below 0.3 w/v% or above 1.0 w/v% (the latter can create stability/tonicity issues, but it is a defined avoidance pathway).

Interaction between dependent claims and independent claim

Even if a competitor designs outside claims 2 and 3, they can still be exposed under claim 1 if they remain within the core elements (finafloxacin topical otic instillation into the external ear canal for AOE or AOM with tubes). In practice, competitors try to break claim 1, not only claims 2 and 3.

---

What is the scope of claims 4 to 6 for dexamethasone-containing finafloxacin otic compositions?

Short answer: The dependent claims restrict the anti-inflammatory agent to dexamethasone and constrain dose to 0.01 to 1.0 wt.%.

Claim 4: any anti-inflammatory agent

This is a broad dependent step that requires the composition “further comprising” an anti-inflammatory agent.

Claim 5: anti-inflammatory agent must be dexamethasone

This is a material narrowing constraint.

Design-around levers:

• Use a different anti-inflammatory (non-steroidal anti-inflammatory, other steroid agents) rather than dexamethasone.
• Adjust formulation so that dexamethasone is absent or below detectable/declared amounts (still subject to proof thresholds and interpretation).

Claim 6: dexamethasone concentration 0.01 to 1.0 wt.%

This adds a quantitative boundary.

Design-around levers:

• Set dexamethasone concentration outside the stated window.
• Remove dexamethasone to avoid both claim 5 and claim 6.

---

How does claim scope translate into patent strength and litigation posture for method-of-treatment otic drops?

Short answer: The patent’s strength is driven by (1) the tube-specific patient condition and (2) the combination of an antibiotic (finafloxacin) with optional steroid (dexamethasone) and excipient ranges.

Likely infringement theory patterns

Given the method-of-treatment framing, enforcement commonly depends on at least one of the following:

• Direct infringement through physician/patient administration matching the claimed steps.
• Induced infringement where product labeling and instructions cause administration for the claimed indication and patient condition.
• Contributory infringement where the product is specially made or adapted for the claimed use.

Likely invalidity vectors (high level, claim-dependent)

Without the specification/claims beyond what you provided and without cited references, the typical invalidity categories for this kind of claim set would include:

• Obviousness combining known finafloxacin otic use with known steroid co-therapy in otitis contexts.
• Anticipation or obviousness of specific formulation windows (concentration and pH) and excipient salts if a reference teaches those ranges.
• Obviousness of tube-specific treatment if tube use is a known subpopulation within acute otitis treatment literature.

The dependent claim ranges (0.3–0.4 w/v% finafloxacin, pH 5.0–6.0, magnesium chloride 0.3–1.0 w/v%, dexamethasone 0.01–1.0 wt.%) also create “range” arguments in both directions: narrow enough to be potentially non-obvious, but also potentially obvious if close-by ranges were already disclosed.

Claim narrowing effects in litigation

In settlement dynamics, a key question is whether the asserted claims are:

• Claim 1 only (broadest and hardest to avoid if a competitor stays within tubo-AOE/AOM finafloxacin topical instillation), or
• Dependent claims (where design-around might be feasible by changing concentration, pH, excipients, or dexamethasone content).

---

What generic entry risks exist for competing finafloxacin otic products during the life of U.S. 9,119,859?

Short answer: The largest risk sits with products that (a) are labeled or promoted for acute otitis externa or media in tube patients, and (b) are finafloxacin otic instillations into the external ear canal. Formulation tweaks can reduce risk for dependent claims but do not necessarily clear claim 1.

Risk map by design-around axis

• Tube condition
  If a product is used in tube patients for AOE/AOM, claim 1 risk remains elevated.

• Finafloxacin inclusion
  Any composition that “comprises finafloxacin” stays inside the core claim element.

• Instillation into external ear canal
  Delivery modality matters. Non-instillation routes likely avoid the literal step, but most otic therapeutics are instillation-based.

• Concentration and pH
  Avoidance of claim 2 is possible by formulating outside 0.3–0.4 w/v% finafloxacin and pH 5.0–6.0.

• Magnesium chloride excipient
  Avoidance of claim 3 is possible by omitting magnesium chloride or using an out-of-range concentration.

• Dexamethasone steroid
  Avoidance of claims 4–6 is possible by using a non-dexamethasone anti-inflammatory or excluding steroid entirely, then staying out of the dexamethasone window if included.

Settlement leverage

A patent with a strong claim-1 “core” often leads to:

• licensing for the core indication and formulation category, or
• settlements that carve out product positioning, patient subgroups, and labeling language to reduce induced infringement exposure.

---

How does U.S. 9,119,859 compare with typical otic antibiotic patent estates (what makes this one different)?

Short answer: Many otic patents focus on antimicrobial compositions or method treatment generally; this one is distinguished by a patient-condition limitation (tympanostomy tubes) coupled with finafloxacin and, in dependent claims, a steroid co-formulation pathway.

Comparative claim breadth

• Broader than formulation-only patents: because it is not restricted solely to exact excipient systems unless dependent claims are asserted.
• Narrower than all-otitis treatments: because it is not “acute otitis externa/media in general,” but specifically “with tympanostomy tubes.”

This combination can drive both enforceability and feasible carving out.

---

What commercial and regulatory facts usually determine exposure to U.S. 9,119,859?

Short answer: Labeling and approved indication language for otic drops, plus any clinical guidance that results in tube-patient administration, determine practical exposure.

FDA Orange Book status and Paragraph IV risk

Whether this patent is listed in the Orange Book for a specific finafloxacin otic NDA/NDA supplement depends on the patent’s listed linkage (drug product, dosage form, and exclusivity code). Since the patent-number-to-Orange-Book linkage is not provided in the input, it cannot be mapped here.

Labeling as the litigation battleground

Because claim 1 is a method requiring treatment with tympanostomy tubes and instillation, label language that:

• states the indication includes tube patients, and
• provides dosing/instruction consistent with instillation into the external ear canal, can be used to connect the product to the claimed method steps.

---

Key patent-claim boundaries (quick reference table)

Claim	Core treated condition	Tube condition	Active ingredient requirement	Delivery/step limitation	Formulation limits that must be met for dependent coverage
1	Acute otitis externa or acute otitis media	Required (“with tympanostomy tubes”)	Composition comprises finafloxacin	Instill into external ear canal	None beyond finafloxacin presence
2	Same as claim 1	Required	Finafloxacin present	Instill into external ear canal	Finafloxacin 0.3–0.4 w/v%; pH 5.0–6.0
3	Same as claim 1	Required	Finafloxacin present	Instill into external ear canal	Plus MgCl2 0.3–1.0 w/v%
4	Same as claim 1	Required	Finafloxacin present	Instill into external ear canal	Plus anti-inflammatory agent
5	Same as claim 1	Required	Finafloxacin present	Instill into external ear canal	Anti-inflammatory agent is dexamethasone
6	Same as claim 1	Required	Finafloxacin present	Instill into external ear canal	Dexamethasone 0.01–1.0 wt.%

---

Key Takeaways

• U.S. 9,119,859 is a tube-specific method-of-treatment claim for AOE or AOM using topical otic finafloxacin instilled into the external ear canal.
• Claim 1 is the strategic risk point: it does not require specific pH, concentration, magnesium chloride, or dexamethasone.
• Dependent claims provide clear formulation design-around targets: finafloxacin 0.3–0.4 w/v%, pH 5.0–6.0, magnesium chloride 0.3–1.0 w/v%, and dexamethasone 0.01–1.0 wt.%.
• Practical litigation exposure for competitors will track label indications and real-world use patterns that match “acute otitis externa/media with tympanostomy tubes” plus finafloxacin otic instillation.

---

FAQs

1) What part of U.S. 9,119,859 is hardest to design around?
Claim 1’s combination of (a) AOE/AOM, (b) tympanostomy tubes in the subject, and (c) instilling a finafloxacin otic composition into the external ear canal.

2) Can a competitor avoid infringement of claims 2 and 3 by changing pH and finafloxacin concentration?
Yes for the dependent-claim formulation limits, by staying outside 0.3–0.4 w/v% finafloxacin and pH 5.0–6.0, and/or omitting or moving magnesium chloride outside 0.3–1.0 w/v%. Claim 1 risk may remain.

3) Does using dexamethasone-free finafloxacin otic avoid claims 4–6?
Yes, if dexamethasone is excluded, because claims 5 and 6 require dexamethasone and its concentration range. Claim 1 still covers finafloxacin tube-patient instillation.

4) How do claims’ “comprising” language affect formulation avoidance?
“Comprising” means additional excipients are allowed; avoidance must come from changing or removing required elements or moving out of specified ranges in dependent claims.

5) What dosing form is most likely to fall within “instilling … into the external ear canal”?
Typical otic drops/solutions designed for canal instillation. Delivery formats that do not result in instillation into the external ear canal would be the primary route to avoid the step.

---

References

1. Provided claims text for U.S. Patent 9,119,859 (user-provided).

Drugs Protected by US Patent 9,119,859

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Fonseca Biosciences	XTORO	finafloxacin	SUSPENSION/DROPS;OTIC	206307-001	Dec 17, 2014		RX	Yes	Yes	9,119,859					TREATMENT OF ACUTE OTITIS EXTERNA

International Family Members for US Patent 9,119,859

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	077372
Australia	2010266120
Brazil	PI1016257
Canada	2765852
Chile	2011003327
China	102470139
China	105687111